This study explores the cost-effectiveness of a supervised moderate-to-high intensity aerobic exercise programme in people diagnosed with Alzheimer’s disease (AD) and estimate incremental cost-effectiveness ratios (ICER) using participant-reported and proxy-reported measures of health-related quality of life (HRQoL) | BMJ Open
Interventions: Control group received treatment as usual. The intervention group performed 1 hour of supervised moderate-to-high intensity aerobic exercise three times weekly for 16 weeks.
Primary and secondary outcomes measures: Different physical, functional and health measures were obtained at inclusion (baseline) and 4 and 16 weeks after. HRQoL (EuroQol-5 Dimensions-5 Levels/EQ-Visual Analogue Scale) was reported by the participants and the primary caregivers as proxy respondents. Differences in HRQOL as reported by the participant and caregiver were explored as were different values of caregiver time with respite from care tasks.
Results: The intervention cost was estimated at €608 and €496 per participant, with and without transport cost, respectively. Participants and caregivers in the intervention group reported a small, positive non-significant improvement in EQ-5D-5L and EQ-VAS after 16 weeks. The ICER was estimated at €72 000/quality-adjusted life year using participant-reported outcomes and €87000 using caregiver-reported outcomes.
Conclusions: The findings suggest that the exercise intervention is unlikely to be cost-effective within the commonly applied threshold values. The cost of the intervention might be offset by potential savings from reduction in use of health and social care.
Full reference: Sopina, E. et al. (2017) Cost-effectiveness of a randomised trial of physical activity in Alzheimer’s disease: a secondary analysis exploring patient and proxy-reported health-related quality of life measures in Denmark. BMJ Open. 7:e015217.
It was already known that between 75% – 89% of care home residents have dementia, but many of these persons do not receive a diagnosis. The Health Innovation Network (HIN) worked with five care homes to design the Dementia Assessment Referral to GP (DeAR-GP) tool.
DeAR-GP is a case finding tool which assists care workers in care homes to identify and support residents showing signs of dementia or confusion. The aim is to achieve better referrals to GPs or other healthcare professionals for prompt review and post-diagnostic support.
Dementia Assessment Referral to GP (DeAR-GP). [Online]: National Institute for Health and Care Excellence (NICE) and Health Innovation Network (HIN), June 2017.
Full Text Link(Note: This article requires a suitable Athens password, a journal subscription or payment for access).
de Waal, H. [and] Jackson, A. (2016). DeAR-GP aids referrals. Nursing Older People. May…
View original post 145 more words
Anthony Scerri , Anthea Innes & Charles Scerri. Dementia training programmes for staff working in general hospital settings – a systematic review of the literature |Aging & Mental Health Vol. 21 , Iss. 8, 2017.
Objectives: Although literature describing and evaluating training programmes in hospital settings increased in recent years, there are no reviews that summarise these programmes. This review sought to address this, by collecting the current evidence on dementia training programmes directed to staff working in general hospitals.
Method: Literature from five databases were searched, based on a number of inclusion criteria. The selected studies were summarised and data was extracted and compared using narrative synthesis based on a set of pre-defined categories. Methodological quality was assessed.
Results: Fourteen peer-reviewed studies were identified with the majority being pre-test post-test investigations. No randomised controlled trials were found. Methodological quality was variable with selection bias being the major limitation. There was a great variability in the development and mode of delivery although, interdisciplinary ward based, tailor-made, short sessions using experiential and active learning were the most utilised. The majority of the studies mainly evaluated learning, with few studies evaluating changes in staff behaviour/practices and patients’ outcomes.
Conclusion: This review indicates that high quality studies are needed that especially evaluate staff behaviours and patient outcomes and their sustainability over time. It also highlights measures that could be used to develop and deliver training programmes in hospital settings.
Cochrane review finds no evidence that Vitamin E supplementation given to people with mild cognitive impairment (MCI) would help to prevent or delay the progression to dementia. Similarly, there is no evidence that Vitamin E supplementation improves cognitive function in people with MCI or dementia due to Alzheimer’s Disease. | Cochrane Database of Systematic Reviews
The review concluded that from limited evidence, there was nothing to suggest that there are either beneﬁts or harms from vitamin E supplements. As the quality of evidence was only moderate, the authors suggest further trials are needed to conﬁrm the ﬁndings.
Pilot research indicates that a chemical in the saliva can be used to differentiate, with relatively high accuracy, between persons who are currently healthy, those with mild cognitive impairment (MCI), and others with Alzheimer’s Disease. Potentially, salivary biomarkers could offer a convenient means of screening people at high risk of developing Alzheimer’s Disease.
Full reference: Yilmaz, A. Geddes, T. & Han, B. et al. Diagnostic biomarkers of Alzheimer’s Disease as identified in saliva using 1H NMR-based metabolomics. Journal of Alzheimer’s Disease: May 11th 2017; 58(2): 355-359.
Related: Dementia saliva testing ‘shows early promise’ | NHS Choices
The Mediterranean and Dietary Approaches to Stop Hypertension diets have been associated with lower dementia risk. We evaluated dietary inflammatory potential in relation to mild cognitive impairment (MCI)/dementia risk | Alzheimer’s & Dementia
Method: Baseline food frequency questionnaires from n = 7085 women (aged 65–79 years) were used to calculate Dietary Inflammatory Index (DII) scores that were categorized into four groups. Cognitive function was evaluated annually, and MCI and all-cause dementia cases were adjudicated centrally. Mixed effect models evaluated cognitive decline on over time; Cox models evaluated the risk of MCI or dementia across DII groups.
Results: Over an average of 9.7 years, there were 1081 incident cases of cognitive impairment. Higher DII scores were associated with greater cognitive decline and earlier onset of cognitive impairment. Adjusted hazard ratios (HRs) comparing lower (anti-inflammatory; group 1 referent) DII scores to the higher scores were group 2-HR: 1.01 (0.86–1.20); group 3-HR: 0.99 (0.82–1.18); and group 4-HR: 1.27 (1.06–1.52).
Conclusions: Diets with the highest pro-inflammatory potential were associated with higher risk of MCI or dementia.
Full reference: Hayden, K.M. et al. (2017) The association between an inflammatory diet and global cognitive function and incident dementia in older women: The Women’s Health Initiative Memory Study. Alzheimer’s & Dementia. Published online: May 19 2017